One Stop Target-to-Hit Platform: Cyclin-dependent kinase 2 (CDK2)
Cyclin-dependent kinase 2 (CDK2) and its respective cyclin E1 and cyclin A2 complexes are essential to driving abnormal growth processes in cancer cells, making these proteins important targets for cancer treatment. To support the discovery of novel CDK2 inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to accelerate hit finding and lead optimization efforts targeting CDK2. Our panel of services also includes high-quality CDK2 and CDK2-complex protein production and established X-ray crystallography protocols.
CDK2-cyclin E1_cyclin A2_platform_v2a
Related Content
Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored...
VIEW RESOURCEIntroduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...
VIEW RESOURCE